Increased ferroptosis of erythrocytes is associated with myelodysplastic syndromes

被引:0
作者
Zhang, Mengying [1 ]
Liu, Mengyuan [1 ]
Yang, Liyan [1 ]
Liu, Yumei [1 ]
Niu, Haiyue [2 ]
Yu, Yating [1 ]
Zhang, Yue [1 ]
Yang, Jinyue [1 ]
Tang, Pu [1 ]
Shao, Zonghong [1 ]
Xing, Limin [1 ]
Wang, Huaquan [1 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Dept Hematol, 154 Anshandao, Tianjin 300052, Peoples R China
[2] Capital Med Univ, Beijing Friendship Hosp, Dept Hematol, Beijing, Peoples R China
关键词
Myelodysplastic syndromes; Ferroptosis; Anemia; Erythrocytes; CELL-DEATH; IRON OVERLOAD; DEFERASIROX; METABOLISM;
D O I
10.1007/s00277-024-05946-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anemia is the most common symptom in patients with myelodysplastic syndromes (MDS). Programmed cell death of erythrocytes is one of the contributing factors to anemia. Ferroptosis is a newly identified form of iron-dependent cell death. The aim of this study is to investigate whether anemia in MDS patients is associated with ferroptosis of nucleated erythrocytes(NEs).We detected lipid peroxidation levels, Fe2+ contents, cell death rates, glutathione (GSH) and malondialdehyde (MDA) levels in bone marrow CD235a+ NEs of MDS patients. Expression levels of ferroptosis-related molecules (ACSL4, GPX4, and SLC7A11) were evaluated through qRT-PCR and Western Blotting. Correlation between these markers and clinical parameters were analyzed. To further substantiate that the mode of cell death with CD235a+ NEs of MDS patients was attributed to the ferroptosis pathway, we applied Fer-1 to inhibit ferroptosis. Cell viability was assessed using CCK8, and changes in ferroptosis-related indicators were simultaneously evaluated. We discover that the ferroptosis level of bone marrow NEs in MDS patients was increased, which is related to anemia and iron overload. Ferroptosis might be one of the causes of anemia in MDS patients.
引用
收藏
页码:4009 / 4020
页数:12
相关论文
共 50 条
  • [41] Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes
    Gao, Yan
    Jin, Feifan
    Zhang, Ping
    Zheng, Cuiping
    Zheng, Xiaoyan
    Xie, Jing
    Lu, Ying
    Tong, Xiangmin
    Du, Jing
    Zhang, Junyu
    Wang, Ying
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [42] Transfusion Support of Patients with Myelodysplastic Syndromes
    Guarente, Juliana
    Tormey, Christopher
    CLINICS IN LABORATORY MEDICINE, 2023, 43 (04) : 669 - 683
  • [43] The myelodysplastic syndromes: diagnosis, prognosis and therapy
    Clissa, Cristina
    Finelli, Carlo
    de Vivo, Antonio
    ITALIAN JOURNAL OF MEDICINE, 2011, 5 (02) : 90 - 97
  • [44] Treatment of lower risk myelodysplastic syndromes
    Park, Sophie
    BULLETIN DU CANCER, 2023, 110 (11) : 1156 - 1161
  • [45] Iron overload in myelodysplastic syndromes (MDS)
    Norbert Gattermann
    International Journal of Hematology, 2018, 107 : 55 - 63
  • [46] Myelodysplastic Syndromes and Iron Chelation Therapy
    Angelucci, Emanuele
    Urru, Silvana Anna Maria
    Pilo, Federica
    Piperno, Alberto
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2017, 9
  • [47] Iron overload in myelodysplastic syndromes (MDS)
    Gattermann, Norbert
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (01) : 55 - 63
  • [48] Impact of iron overload in myelodysplastic syndromes
    Fenaux, Pierre
    Rose, Christian
    BLOOD REVIEWS, 2009, 23 : S15 - S19
  • [49] Transfusions and iron chelation in myelodysplastic syndromes
    Pascal, Laurent
    BULLETIN DU CANCER, 2023, 110 (11) : 1176 - 1182
  • [50] Myelodysplastic Syndromes Classification and Risk Stratification
    Komrokji, Rami S.
    Zhang, Ling
    Bennett, John M.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 443 - +